TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04775615
Drug: DDO-3055 tablets；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
Study: NCT04775615
Drug: DDO-3055 tablets；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
Study: NCT05443178
Drug: Nivaquine ® (Chloroquine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose escalation and extension trial
Study: NCT05649618
Drug: Cyclophosphamide Capsules
Normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT05047159
Drug: drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no restriction on the choice of therapeutic drugs.
Study: NCT05474690
Drug: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
Study: NCT05081986
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to cycloserine capsule
Study: NCT05721287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
Study: NCT05985629
Drug: IPACK
Normalized name: Emend TriPack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
Study: NCT05985629
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
Study: NCT06716151
Drug: HB0034
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Study: NCT06716151
Drug: HB0034 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0034 matching Palcebo
Study: NCT03523338
Drug: ADT (Standard of Care)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
Study: NCT06733935
Drug: NKX019
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Study: NCT06733935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion
Study: NCT06732648
Drug: HRS8179 blank preparation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS8179 blank preparation.
Study: NCT04261387
Drug: LUT014 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application qd for 28 days
Study: NCT04261387
Drug: Placebo for LUT014 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for qd topical application for 28 days
Study: NCT06733519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to TH-104
Study: NCT06729073
Drug: Diclofenac sodium gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical administration
Study: NCT06729073
Drug: Diclofenac diethylamine 1.16% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration
Study: NCT06381557
Drug: Zhengyuan Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhengyuan capsules, 4 capsules at a time, 3 times per day;
Study: NCT06381557
Drug: Placebo contains 5%-10% Zhengyuan Capsule total mixed powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
Study: NCT06251089
Drug: CPC mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07% CPC mouthwash
Study: NCT06251089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of the CPC mouthwash
Study: NCT06372184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
Study: NCT04284059
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
Study: NCT05477108
Drug: Treatment A (BGF MDI HFO with oral activated charcoal)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
Study: NCT05477108
Drug: Treatment B (BGF MDI HFA with oral activated charcoal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
Study: NCT05137119
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin
Study: NCT04950881
Drug: Bradycardia Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
Study: NCT05759234
Drug: HS248 pieces
Approvals — FDA: no, EMA: no, PMDA: no
Description: The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
Study: NCT04736745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for injection
Study: NCT04168879
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
Study: NCT04187547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
Study: NCT04412395
Drug: Placebo of excipient(s) will be administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the equivalent excipient will be administered to placebo group
Study: NCT05507411
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg Q3W
Study: NCT03890341
Drug: Drospirenone/Ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
Study: NCT00348582
Drug: Ketorolac, Nepafenac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002344
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05524194
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Study: NCT04833023
Drug: Haldol 2mg/ml oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).
Study: NCT06455813
Drug: Macrogol 3350 and electrolytes
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
Study: NCT06464393
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
Study: NCT05808725
Drug: Norvasc 5 mg tablets of Pfizer Labs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvasc 5 mg is given to R Fasting
Study: NCT04978493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04667117
Drug: iDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
Study: NCT04815551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is sterile liquid for IV infusion.
Study: NCT05219318
Drug: Combination PD-1/PD-L1 ICI + VEGFR-TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
Study: NCT05304910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Study: NCT05850689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily
Study: NCT01511835
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 400mcg; 1 cp/die
Study: NCT05220228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose / sucrose placebo
Study: NCT05016869
Drug: fruquintinib plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W
Study: NCT05553678
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
Study: NCT02503176
Drug: KCT-0809 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05618353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05020652
Drug: TQ05105 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
Study: NCT05886868
Drug: BL0020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage.
Study: NCT04724655
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
Study: NCT04686448
Drug: propofol-fentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Study: NCT06434961
Drug: SHR6508 plus oral placebo tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6508 plus oral placebo tablets
Study: NCT05761431
Drug: SYHX2008 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration on Day 1.
Study: NCT05761431
Drug: Sandostatin ® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration on Day 1.
Study: NCT05761431
Drug: Placebo to SYHX2008 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration on Day 1.
Study: NCT06042647
Drug: 0.01% Halobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
Study: NCT05553691
Drug: SPL026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT04182490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical appearing placebo
Study: NCT04393883
Drug: A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Approvals — FDA: no, EMA: no, PMDA: no
Description: (A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Study: NCT04393883
Drug: B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Approvals — FDA: no, EMA: no, PMDA: no
Description: (B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Study: NCT04597320
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.
Study: NCT06196762
Drug: XKH002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/4 mL/vial（60 mg/mL）
Study: NCT05054023
Drug: Soulagel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: topic gel
Study: NCT05054023
Drug: Arthrosyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: topic gel
Study: NCT04773587
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream - Vehicle
Study: NCT05814523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as IV solution.
Study: NCT05814523
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Study: NCT05632627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT04782323
Drug: aQII-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04782323
Drug: aQII-3 Investigational
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04782323
Drug: aQII-6 Investigational
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04782323
Drug: aQII-9 Investigational
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04782323
Drug: aQII-10 Investigational
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04782323
Drug: aQII-11 Investigational
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT04709536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Study: NCT00239317
Drug: Tamusulosin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04617028
Drug: Placebo to match Hydroxycarbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Hydroxycarbamide Tablets administered orally twice daily
Study: NCT06365580
Drug: Kylo-0603 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated orally.
Study: NCT06365580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated orally.
Study: NCT05148715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
Study: NCT06264440
Drug: BIIB122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05684965
Drug: XTX301
Approvals — FDA: no, EMA: no, PMDA: no
Description: XTX301 monotherapy
Study: NCT06463548
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
Study: NCT05851508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanal injection with saline, natriumchloride 0.9%
Study: NCT05393817
Drug: caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
Study: NCT05143762
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo 10 ml normal saline IV.
Study: NCT06554470
Drug: Systemic Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
Study: NCT06554470
Drug: Local Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
Study: NCT04896489
Drug: Hydrocortisone 20 MG
Normalized name: hydrocortisone 20 MG
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive Hydrocortisone 20 MG
Study: NCT05818735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
Study: NCT05415150
Drug: Thrombolytic Agent
Normalized name: Thrombolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may receive one or more of the treatment options
Study: NCT06634927
Drug: Ozempic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
Study: NCT06634927
Drug: HDG1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
Study: NCT05802810
Drug: [14C]JT001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
Study: NCT05787418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 8 times per day for 7 consecutive days
Study: NCT05369052
Drug: contezolid acefosamil (IV)/contezolid (PO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Study: NCT05640674
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-opioid
Study: NCT05640674
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid